TetraGenetics, a biopharmaceutical company developing novel antibody therapeutics for ion-channel related diseases, announced the discovery of functional antibodies against Nav1.8.
The company has the leading drug discovery platform (TetraExpress™) for identifying antibodies targeting ion channels and other transmembrane proteins.
A multi-platform antibody discovery approach (phage display, llama immunization) has enabled TetraGenetics to identify functional anti-Nav1.8 antibodies that selectively inhibit Nav1.8 currents in a recombinant cell line. A lead antibody molecule demonstrates significant inhibition of activity in sensitive human dorsal root ganglion (DRG) neurons, at a level that translates to clinical analgesia.
“The discovery of these functional antibodies represents a clear industry breakthrough and accelerates the company’s transition from research to full scale drug development,” said Doug Kahn, CEO of TetraGenetics.
A video introduction to TetraGenetics presentation at the Antibody Engineering & Therapeutics Virtual Conference is available here.